Overview
MOA
Impact
X
Procedure
Guidelines
Resources
Clinical Library
Reimbursement
Grants
Order Cysview
Overview
White vs. Blue Light
Patient Stories
Bladder Cancer Overview
X
Resources
Home
BLC™ with Cysview®
>
News
Health Care Professionals
>
Find a BLC with Cysview Center
X
Cysview LogoHamburger Menu Icon
Menu
Find a BLC with Cysview Center

References

1 "Key Statistics for Bladder Cancer.” American Cancer Society, January 2017. Website URL. Accessed August 2017.

2 Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in
patients with nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1907-1913.

3 Fradet Y, Grossman HB, Gomella L, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178(1):68-73.

4 Jocham D, Witjes F, Wagner S, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174(3):862-866.

5 Schmidbauer J, Witjes F,Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171(1):135-138.

6 Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol. 2007;178(1):62-67.

7 Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int. 2011;108(8 pt 2):E297-303.

8 Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol.2009;27(3):295-300.

9 Burger M et al. European Urology 2013; EURURO-5062; No. of Pages 9.

10 Photodynamic Diagnosis of Bladder Cancer: Evidence Base. NHS – Technology Adoption Centre. Website URL. Accessed April 2016.

11 Sylvester RJ et al. Eur Urol 2006; 49: 466-467.

12 Denzinger S, Burger M, Walter B et al. Clinically Relevant Reduction in Risk of Recurrence of Superficial Bladder Cancer Using 5-Aminolevulinic Acid- Induced Fluorescence Diagnosis: 8-Year Results of Prospective
Randomized Study. J Uro. 2007;69(4):675-679.

13 Stenzl A et al.J Urol. 2010; 184(5):1907-1913 and Lane et al. J Urol. Vol. 197, 596-601, March 2017.

14 Data on File. Photocure ASA. 2016.

15 “SEER Cancer Stat Facts: Bladder Cancer.” National Cancer Institute. Website URL. Accessed August 2017.

16 Cysview [prescribing information]. Princeton, NJ: Photocure ASA; 2011.

17 Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. American Urological Association.

18 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) –
Bladder Cancer. National Comprehensive Cancer Network. PDF Source. Accessed April 2016.

19 Herr HW. J Urol 1999; 162: 74-76.

20 Divrik RT et al. J Urol 2006; 175: 1641-16.

21 Adiyat KT et al. Urology 2010; 75: 365-369. 

22 Bladder Cancer. American Cancer Society. PDF Source. Accessed August 2017.

23 “Treating Bladder Cancer.” Bladder Cancer Advocacy Network (BCAN), April 2017. Website URL. Accessed August 2017.

BACK TO TOP